Company intelligence / Profile preview
Novochizol SA
Monthey, Valais, Switzerlandnovochizol.ch ↗
- Ownership
- Private
- Development stage
- Preclinical
01
Overview
Novochizol’s technology has demonstrated strong preclinical safety and efficacy in animal models, showing local, sustained release with minimal systemic effects. No human clinical trials have been reported as of June 2025. The company is pursuing regulatory qualification for pharmaceutical use.
- Therapeutic areas
- OncologyPulmonologyDermatologyRheumatology
- Modalities
- Small moleculesPeptidesNucleic acidsProteins
- Industry
- Biotech
02
Drug pipeline
1 asset03
Partnerships
Boehringer Ingelheim – winner of the opnMe novel drug delivery solutions contest, indicating collaboration or recognition by a major pharma partner.
Beyond the preview
Go deeper on Novochizol SA.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Novochizol SA.